How Could We Further Improve the Gilteritinib Maintenance After Allogeneic Hematopoietic Cell Transplantation in <i>FLT3</i>-Mutated AML? | J Clin Oncol;: JCO2400566, 2024 Jul 31. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

How Could We Further Improve the Gilteritinib Maintenance After Allogeneic Hematopoietic Cell Transplantation in FLT3-Mutated AML?

Fuji, Shigeo.

Affiliation

Fuji S; Shigeo Fuji, MD, PHD, Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.

J Clin Oncol ; : JCO2400566, 2024 Jul 31.

Article in En | MEDLINE | ID: mdl-39083709

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Clin Oncol Year: 2024 Document type: Article Affiliation country:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Clin Oncol Year: 2024 Document type: Article Affiliation country: